Wyeth warns shareholders on mini-tender offer

11 December 2006

US drug major Wyeth say that it has been notified of an unsolicited mini-tender offer made by TRC Capital Corp, a private Canadian investment company, offering to purchase from Wyeth stockholders up to 2,000,000 shares, or approximately 0.15%, of the firm's outstanding common stock. The offer price of $47.00 per share represents a 3.45% discount to the $48.68 closing price for Wyeth stock on the New York Stock Exchange on November 21, 2006, the day before the date of the offer.

Wyeth stated that it does not recommend or endorse this unsolicited offer, and is not affiliated with TRC, the offer or the offer to purchase. It explained that Wyeth is one of many companies that TRC has targeted for a mini-tender. These offers seek less than 5% of a company's stock and avoid many disclosure and procedural requirements under US federal securities laws.

The US Securities and Exchange Commission has issued an investor alert regarding mini-tender offers on its web site, saying that these "have been increasingly used to catch investors off guard," and that investors "may end up selling their securities at below-market prices."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight